BriggsFBS. Racial and ethnic disease phenotype differences are driven by genetics: Yes. Mult Scler J2024; 30(5S): 5–8.
2.
Langer-GouldA. Racial and ethnic disease phenotype differences are driven by genetics: No. Mult Scler J2024; 30(5S): 9–11.
3.
MungerKCRotsteinDL. Racial and ethnic disease phenotype differences are driven by genetics: Commentary. Mult Scler J2024; 30(5S): 11–12.
4.
McGinleyMP. Improving access to MS care through technology. Mult Scler J2024; 30(5S): 13–18.
5.
MotlRW. Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs. Mult Scler J2024; 30(5S): 36–40.
6.
PiluttiLADonkersSJ. Exercise as a Therapeutic Intervention in Multiple Sclerosis. Mult Scler J2024; 30(5S): 30–35.
7.
KochMWCamara-LemarroyCStrijbisE, et al. Selecting informative patients for phase 2 progressive trials in MS: Design considerations for phase 2 clinical trials in progressive MS. Mult Scler J2024; 30(5S): 41–47.
8.
GaitánMIMarquezRVAyerbeJ, et al. Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation. Mult Scler J2024; 30(5S): 48–60.
9.
HochstetlerALehtinenMK. Choroid plexus as a mediator of CNS inflammation in multiple sclerosis. Mult Scler J2024; 30(5S): 19–23.
10.
BergslandNDwyerMGZivadinovR. Imaging the choroid plexus. Mult Scler J2024; 30(5S): 24–29.
